Comparative Pharmacology
Head-to-head clinical analysis: RELEUKO versus RYZNEUTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RELEUKO versus RYZNEUTA.
RELEUKO vs RYZNEUTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation, differentiation, and activation of neutrophil progenitor cells.
Granulocyte colony-stimulating factor, acts on hematopoietic cells by binding to G-CSF receptors, stimulating proliferation, differentiation, and release of neutrophils.
5 mcg/kg subcutaneously once daily for up to 10 days or until neutrophil count >10,000/mcL after nadir.
6 mg subcutaneously once per chemotherapy cycle, administered approximately 24 hours after cytotoxic chemotherapy. Do not administer within the period from 14 days before to 24 hours after administration of cytotoxic chemotherapy.
None Documented
None Documented
Terminal half-life approximately 5.3 hours (range 4.5–6.2 hours) in adults with normal renal function.
The terminal elimination half-life is approximately 20–30 hours in healthy volunteers and up to 40 hours in cancer patients receiving chemotherapy, reflecting FcRn-mediated recycling and delayed clearance.
Primarily renal (approximately 70% as intact drug). Minor biliary/fecal elimination (<5%).
Renal clearance accounts for approximately 70% of total clearance, with the remainder via hepatic/biliary/fecal routes. Unchanged drug is minimal as efbemalenograstim alfa is a recombinant fusion protein expected to undergo catabolism to small peptides and amino acids.
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor